GEP201706716B - Optimised subcutaneous therapeutic agents - Google Patents

Optimised subcutaneous therapeutic agents

Info

Publication number
GEP201706716B
GEP201706716B GEAP201313632A GEAP2013013632A GEP201706716B GE P201706716 B GEP201706716 B GE P201706716B GE AP201313632 A GEAP201313632 A GE AP201313632A GE AP2013013632 A GEAP2013013632 A GE AP2013013632A GE P201706716 B GEP201706716 B GE P201706716B
Authority
GE
Georgia
Prior art keywords
optimised
therapeutic agents
subcutaneous therapeutic
subcutaneous
blood coagulation
Prior art date
Application number
GEAP201313632A
Other languages
English (en)
Inventor
William Henry
Richard Wolf-Garraway
John Charles Mayo
Michael James Earl
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en
Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en
Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of GEP201706716B publication Critical patent/GEP201706716B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
GEAP201313632A 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents GEP201706716B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GBGB1213712.1A GB201213712D0 (en) 2012-08-01 2012-08-01 Modified therapeutic agents
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents

Publications (1)

Publication Number Publication Date
GEP201706716B true GEP201706716B (en) 2017-08-10

Family

ID=48190923

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201313632A GEP201706716B (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents

Country Status (29)

Country Link
US (2) US20150086524A1 (OSRAM)
EP (1) EP2838566A2 (OSRAM)
JP (3) JP2015512927A (OSRAM)
KR (1) KR102137290B1 (OSRAM)
CN (1) CN104411335A (OSRAM)
AP (1) AP2014008049A0 (OSRAM)
AU (3) AU2013248296A1 (OSRAM)
BR (1) BR112014025737A2 (OSRAM)
CA (1) CA2869993C (OSRAM)
CL (1) CL2014002773A1 (OSRAM)
CO (1) CO7151496A2 (OSRAM)
CR (1) CR20140475A (OSRAM)
EA (1) EA033469B1 (OSRAM)
EC (1) ECSP14023048A (OSRAM)
GB (3) GB2516388A (OSRAM)
GE (1) GEP201706716B (OSRAM)
HK (1) HK1200695A1 (OSRAM)
IL (1) IL235129B (OSRAM)
IN (1) IN2014DN08598A (OSRAM)
MD (1) MD20140123A2 (OSRAM)
MX (2) MX2014012512A (OSRAM)
MY (1) MY190257A (OSRAM)
NI (1) NI201400122A (OSRAM)
NZ (1) NZ701205A (OSRAM)
PE (1) PE20150226A1 (OSRAM)
PH (1) PH12014502314B1 (OSRAM)
SG (1) SG11201406492YA (OSRAM)
WO (1) WO2013156488A2 (OSRAM)
ZA (1) ZA201407370B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498815B (zh) * 2013-12-30 2022-07-22 江苏众红生物工程创药研究院有限公司 重组人激肽释放酶的化学修饰物及其应用
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
WO2016198641A1 (en) * 2015-06-12 2016-12-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
CN109998994B (zh) * 2018-02-13 2021-12-07 四川大学 包含药物的柔性脂质体及其制备方法
EP4106798A1 (en) 2020-02-17 2022-12-28 Biotest AG Subcutaneous administration of factor viii
CN115443147A (zh) * 2020-04-23 2022-12-06 伊莱利利公司 抗体的皮下吸收和生物利用度

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (OSRAM) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
AU690083B2 (en) 1992-09-28 1998-04-23 Research Corporation Technologies, Inc. New reagents for peptide couplings
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインｃ誘導体
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CA2177644A1 (en) * 1995-05-31 1996-12-01 Peter D. Senter Polymeric prodrugs for beta-lactamase and uses thereof
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
WO2001082943A2 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
WO1999043357A1 (en) * 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
CA2490360A1 (en) * 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
KR101085375B1 (ko) * 2003-02-26 2011-11-21 넥타르 테라퓨틱스 중합체-인자 ⅷ 부분 콘쥬게이트
AU2004228793B2 (en) * 2003-04-08 2009-10-08 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US20130137157A1 (en) * 2003-04-09 2013-05-30 Novo Nordisk A/S Glycopegylated factor vii and factor viia
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
ATE431150T1 (de) 2004-03-04 2009-05-15 Eisai R&D Man Co Ltd Zusammensetzung mit benzamidin-derivat und verfahren zur stabilisierung von benzamidin- derivat
MXPA06015234A (es) * 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Conjugados de fraccion polimero-factor ix.
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP1937719A4 (en) * 2005-08-19 2010-11-24 Novo Nordisk As FACTOR VII AND GLYCOPEGYLE VIIA FACTOR
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
EP2059527B1 (en) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Modified glycoproteins
EP2101821B1 (en) 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
KR101503085B1 (ko) * 2006-12-27 2015-03-16 넥타르 테라퓨틱스 방출가능한 연결을 갖는 폰 빌레브란드 인자­ 및 인자 ⅷ­폴리머 컨주게이트
WO2008081024A1 (en) 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
KR20150067772A (ko) 2007-04-13 2015-06-18 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
EP2014299A1 (en) 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
ES2597849T3 (es) 2007-10-09 2017-01-23 Polytherics Limited Proteínas y péptidos conjugados novedosos
JP5733744B2 (ja) 2007-10-16 2015-06-10 ファーマサイクリックス，インク． 凝血因子ＶＩＩａモジュレーターの製造、組成物及び使用
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CA2721362A1 (en) * 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
MX2010011672A (es) * 2008-04-24 2011-03-02 Celtic Pharma Peg Ltd Conjugados del factor ix con vidas medias extendidas.
CN102083459A (zh) * 2008-05-23 2011-06-01 诺沃-诺迪斯克保健股份有限公司 包括含有peg化的gla-结构域的蛋白质的低粘度组合物
DK2374481T3 (en) 2008-07-21 2016-02-01 Polytherics Ltd New reagents and methods for the conjugation of biological molecules
CA2738064C (en) * 2008-10-15 2013-03-19 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
AU2009305612B2 (en) * 2008-10-17 2015-05-21 Takeda Pharmaceutical Company Limited Modified blood factors comprising a low degree of water soluble polymer
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
MX2012001207A (es) * 2009-07-27 2012-05-08 Baxter Int Conjugados proteicos de coagulacion sanguínea.
JP5914363B2 (ja) * 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
NZ605972A (en) * 2010-07-30 2015-04-24 Baxter Healthcare Sa Nucleophilic catalysts for oxime linkage
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates

Also Published As

Publication number Publication date
PE20150226A1 (es) 2015-02-14
WO2013156488A2 (en) 2013-10-24
AP2014008049A0 (en) 2014-11-30
CO7151496A2 (es) 2014-12-29
KR20140146171A (ko) 2014-12-24
MX2020014208A (es) 2021-03-09
AU2018200111B2 (en) 2019-11-07
IL235129A0 (en) 2014-12-31
MY190257A (en) 2022-04-11
JP2015512927A (ja) 2015-04-30
AU2020200842A1 (en) 2020-02-27
NI201400122A (es) 2016-12-02
PH12014502314A1 (en) 2015-01-12
SG11201406492YA (en) 2014-11-27
ECSP14023048A (es) 2015-11-30
MD20140123A2 (ro) 2015-04-30
EA201491702A1 (ru) 2015-03-31
GB2516388A (en) 2015-01-21
JP2019131593A (ja) 2019-08-08
CA2869993A1 (en) 2013-10-24
KR102137290B1 (ko) 2020-07-23
WO2013156488A3 (en) 2014-01-16
GB201910184D0 (en) 2019-08-28
AU2013248296A1 (en) 2014-11-13
CR20140475A (es) 2015-01-23
NZ701205A (en) 2016-02-26
US20150086524A1 (en) 2015-03-26
CA2869993C (en) 2023-05-23
AU2018200111A1 (en) 2018-01-25
US11351112B2 (en) 2022-06-07
PH12014502314B1 (en) 2020-01-31
IL235129B (en) 2022-06-01
CL2014002773A1 (es) 2015-01-16
GB201910190D0 (en) 2019-08-28
IN2014DN08598A (OSRAM) 2015-05-22
EA033469B1 (ru) 2019-10-31
JP2018024684A (ja) 2018-02-15
MX2014012512A (es) 2015-01-15
CN104411335A (zh) 2015-03-11
BR112014025737A2 (pt) 2017-07-04
ZA201407370B (en) 2017-09-27
GB201418864D0 (en) 2014-12-03
HK1200695A1 (en) 2015-08-14
US20180036229A1 (en) 2018-02-08
EP2838566A2 (en) 2015-02-25
JP6550107B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
GEP201706716B (en) Optimised subcutaneous therapeutic agents
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
EA201590115A8 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
EA201991484A1 (ru) Лекарственные формы энзалутамида
NZ707477A (en) Activin-actrii antagonists and uses for treating bone and other disorders
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
CL2014002846A1 (es) Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder
EA201490509A1 (ru) Биосовместимый катетер
IL222201A (en) Preparation created from an in vitro culture of dedifferentiated, non-elicited cells of the argania tree, use thereof for treating skin ageing, inflammation and scarring and production thereof
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
EA201391438A1 (ru) Производные сулиндака, применение и получение указанных производных
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
PH12015500306A1 (en) Arry-520 for use in treating cancer in a patient with low aag
UA72875U (ru) Способ хирургического лечения деформации лобно-височной области и птоза брови
RU2013153574A (ru) Способ лечения синовитов и/или синовиальных кист
RU2012130739A (ru) Комбинированный лекарственный препарат, предназначенный для подготовки к диагностической или лечебной транспищеводной медицинской манипуляции